HBW Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Tysabri Webcast Citation May Signal That FDA Could Treat All Social Media Interactions As Promotional; Biogen's PML Strategy Also Takes A Hit

Executive Summary

FDA appears to be gearing up to treat social media interactions as promotional even when they are aimed solely at informing physicians
Advertisement

Related Content

Advertising Regulation Wiki? Industry Wants Authoritative But Frequently Updated FDA Guidance (And/Or Regs) On Internet Drug Promotion
Tysabri Risk Communication Goes Beyond REMS With Monthly Update For Docs
Who's Liable For Online Content? Pharma, Marketers Disagree (Slightly)
EU Regulators Up The Number of Tysabri-Related PML Cases, Re-Open a Safety Review
EU Regulators Up The Number of Tysabri-Related PML Cases, Re-Open a Safety Review
Internet Promotions Must Be Redesigned After FDA Cites Sponsored Web Links

Topics

Advertisement
UsernamePublicRestriction

Register

PS052123

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel